Summary of COVID-19 pomotrelvir studies

1. Borroto-Esoda et al., SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir

230 patient pomotrelvir early treatment RCT: 1% worse recovery (p=1) and 252% worse results (p=0.1).
RCT 242 symptomatic outpatients showing no significant difference in viral clearance or symptom resolution with pomotrelvir treatment initiated within 5 days of symptom onset. Based on the description provided it is not clear why the number of censored patients changes in the treatment group between the 5, 12, and 14 symptom results. The event count and percentage reported for the 12 symptom result do not match. Authors also compare viral clearance based on infectious virus assay (IVA), RAT, and PCR, which shows that PCR/RAT results are often positive when IVA shows no infectious virus.
Feb 2024, Microbiology Spectrum, https://journals.asm.org/doi/10.1128/spectrum.02980-23, https://c19p.org/borrotoesoda